536 related articles for article (PubMed ID: 26962685)
21. Microphthalmia-associated transcription factor controls the DNA damage response and a lineage-specific senescence program in melanomas.
Giuliano S; Cheli Y; Ohanna M; Bonet C; Beuret L; Bille K; Loubat A; Hofman V; Hofman P; Ponzio G; Bahadoran P; Ballotti R; Bertolotto C
Cancer Res; 2010 May; 70(9):3813-22. PubMed ID: 20388797
[TBL] [Abstract][Full Text] [Related]
22. Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression.
Kono M; Dunn IS; Durda PJ; Butera D; Rose LB; Haggerty TJ; Benson EM; Kurnick JT
Mol Cancer Res; 2006 Oct; 4(10):779-92. PubMed ID: 17050671
[TBL] [Abstract][Full Text] [Related]
23. A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITF
Smith MP; Rana S; Ferguson J; Rowling EJ; Flaherty KT; Wargo JA; Marais R; Wellbrock C
Pigment Cell Melanoma Res; 2019 Mar; 32(2):280-291. PubMed ID: 30277012
[TBL] [Abstract][Full Text] [Related]
24. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
Jiang X; Zhou J; Giobbie-Hurder A; Wargo J; Hodi FS
Clin Cancer Res; 2013 Feb; 19(3):598-609. PubMed ID: 23095323
[TBL] [Abstract][Full Text] [Related]
25. The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα.
Smith MP; Sanchez-Laorden B; O'Brien K; Brunton H; Ferguson J; Young H; Dhomen N; Flaherty KT; Frederick DT; Cooper ZA; Wargo JA; Marais R; Wellbrock C
Cancer Discov; 2014 Oct; 4(10):1214-1229. PubMed ID: 25256614
[TBL] [Abstract][Full Text] [Related]
26. MITF Modulates Therapeutic Resistance through EGFR Signaling.
Ji Z; Erin Chen Y; Kumar R; Taylor M; Jenny Njauw CN; Miao B; Frederick DT; Wargo JA; Flaherty KT; Jönsson G; Tsao H
J Invest Dermatol; 2015 Jul; 135(7):1863-1872. PubMed ID: 25789707
[TBL] [Abstract][Full Text] [Related]
27. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT
Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma.
Gopal YN; Rizos H; Chen G; Deng W; Frederick DT; Cooper ZA; Scolyer RA; Pupo G; Komurov K; Sehgal V; Zhang J; Patel L; Pereira CG; Broom BM; Mills GB; Ram P; Smith PD; Wargo JA; Long GV; Davies MA
Cancer Res; 2014 Dec; 74(23):7037-47. PubMed ID: 25297634
[TBL] [Abstract][Full Text] [Related]
29. Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-Kit.
Sabbah M; Krayem M; Najem A; Sales F; Miller W; Del Rincon S; Awada A; Ghanem GE; Journe F
Mol Cancer Res; 2021 Jul; 19(7):1221-1233. PubMed ID: 33741716
[TBL] [Abstract][Full Text] [Related]
30. Simultaneous suppression of MITF and BRAF V600E enhanced inhibition of melanoma cell proliferation.
Kido K; Sumimoto H; Asada S; Okada SM; Yaguchi T; Kawamura N; Miyagishi M; Saida T; Kawakami Y
Cancer Sci; 2009 Oct; 100(10):1863-9. PubMed ID: 19659611
[TBL] [Abstract][Full Text] [Related]
31. Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models.
Liu Y; Hawkins OE; Vilgelm AE; Pawlikowski JS; Ecsedy JA; Sosman JA; Kelley MC; Richmond A
Clin Cancer Res; 2015 Dec; 21(23):5338-48. PubMed ID: 26152738
[TBL] [Abstract][Full Text] [Related]
32. Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation.
Wellbrock C; Marais R
J Cell Biol; 2005 Aug; 170(5):703-8. PubMed ID: 16129781
[TBL] [Abstract][Full Text] [Related]
33. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
34. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
35. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
[TBL] [Abstract][Full Text] [Related]
36. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF.
Wellbrock C; Rana S; Paterson H; Pickersgill H; Brummelkamp T; Marais R
PLoS One; 2008 Jul; 3(7):e2734. PubMed ID: 18628967
[TBL] [Abstract][Full Text] [Related]
37. E3 ubiquitin ligase PARK2, an inhibitor of melanoma cell growth, is repressed by the oncogenic ERK1/2-ELK1 transcriptional axis.
Montagnani V; Maresca L; Apollo A; Pepe S; Carr RM; Fernandez-Zapico ME; Stecca B
J Biol Chem; 2020 Nov; 295(47):16058-16071. PubMed ID: 32938713
[TBL] [Abstract][Full Text] [Related]
38. Phosphorylation of MITF by AKT affects its downstream targets and causes TP53-dependent cell senescence.
Wang C; Zhao L; Su Q; Fan X; Wang Y; Gao S; Wang H; Chen H; Chan CB; Liu Z
Int J Biochem Cell Biol; 2016 Nov; 80():132-142. PubMed ID: 27702651
[TBL] [Abstract][Full Text] [Related]
39. Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF.
Haq R; Shoag J; Andreu-Perez P; Yokoyama S; Edelman H; Rowe GC; Frederick DT; Hurley AD; Nellore A; Kung AL; Wargo JA; Song JS; Fisher DE; Arany Z; Widlund HR
Cancer Cell; 2013 Mar; 23(3):302-15. PubMed ID: 23477830
[TBL] [Abstract][Full Text] [Related]
40. Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-M(high) melanoma cell populations.
Hartman ML; Talar B; Sztiller-Sikorska M; Nejc D; Czyz M
Oncotarget; 2016 Feb; 7(8):9026-40. PubMed ID: 26824319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]